Answers are grounded in this paper and cite their sources.
Shows ENT-21 effectively lowers glucose levels in db/db mice, indicating promising oral treatment options.
Introduction and Objective: PTP1b is a key target for T2DM and obesity treatment due to its role in hypothalamic insulin and leptin signaling, but one that has eluded successful drug development. We previously described ENT-03, a subcutaneously injectable, centrally acting PTP1b inhibitor, to be safe in Phase 1a trial. Here, we identify ENT-21, an orally available ENT-03 derivative, with 3D models showing ENT-03 allosteric inhibition of PTP1b. Methods: Five ENT-03 derivatives were tested for bioavailability in male SD rats dosed at 40 mg/kg (po for derivatives, po and sc for ENT-03). Blood levels were monitored from 1 to 72 hours. ENT-21, a prodrug of ENT-03, was tested for efficacy in normalizing glucose levels in db/db mice. Molecular modeling of ENT-03 binding to PTP1b used x-ray crystallographic data combined with modeling that resolved the α7 helix, followed by docking studies targeting the allosteric site. Results: Four of the ENT-03 derivatives had improved blood levels after oral gavage. ENT-21 was rapidly converted to ENT-03 in the blood, exhibiting an identical time course as sc ENT-03 (T1/2 = 24 h). ENT-21 demonstrated 8-fold higher plasma Cmax and AUC0-inf than po ENT-03. The AUC0-inf, T1/2 of 24 h, and Tmax of 8 h predict that QD or BID dosing of ENT-21 yield therapeutic concentrations of ENT-03 in blood. A dose of ENT-21 (40 mg/kg, po) was as effective as ENT-03 (10 mg/kg ip) in lowering fasting glucose levels in db/db mice. A molecular model of ENT-03 was developed, featuring very strong docking scores within the allosteric site, comprised of α3, α6 and α7 helices. This binding induces conformational changes in the W-P-D loop, rendering the catalytic site inoperable. Comparison of the PTP1b and SHP2 sequences demonstrated significant differences in the allosteric site between these and other tyrosine phosphatases, explaining the selectivity of ENT-03 for PTP1b. Conclusion: ENT-21 is a prodrug of ENT-03 suitable for oral dosing. Modeling reveals that ENT-03 allosterically inhibits PTP1b and predicts high selectivity for this target. Disclosure W.A. Kinney: None. R.P. Ford: None. J.P. Kulp: None. M.B. Zemel: None. G.A. Fleming: Consultant; Current; Metabolics Pharma, Diamyd, Diasome. Stock/Shareholder; Current; NuSirt, Elvinix. Consultant; Current; TixiMed. Stock/Shareholder; Current; Serpin. Consultant; Current; BioAge, vTv Therapeutics, AdioPharm, Regor. A.C. Moses: Consultant; Current; Virta Health Corp., Vertex Pharmaceuticals Incorporated, Novo Nordisk A/S. Advisory Panel; Current; TixiMed. Stock/Shareholder; Current; Minutia. Advisory Panel; Current; Kailera, Metabolics Pharma. Consultant; Current; 3D Communication. R.S. Larson: None.
No takes yet. Share an insight, caveat, or question.
Kinney et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: